FH-EB02

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameFH-EB02
Drug Alias NameFH-EB02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCD276 antigen inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsCD276 antigenEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Pulmonary Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Pulmonary Hospital
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A